Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

NCT01321567 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT01321567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01321567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
Lead sponsor
Eisai Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
January 1, 2011
Completion date
August 1, 2013
Enrollment
2,157 (actual)
Sites
447

Conditions

As the registry lists them; a condition with its own page is linked.

refractory reflux esophagitis